Re: Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome Reply

被引：0

作者：

Lainas, T. G. ^{[1
]}

Kolibianakis, E. M. ^{[2
]}

机构：

[1] Eugonia Unit Assisted Reprod, Athens, Greece

[2] Aristotle Univ Thessaloniki, Human Reprod Unit, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp,Med Sch, GR-54006 Thessaloniki, Greece

来源：

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 2015年 / 122卷 / 04期

关键词：

D O I：

10.1111/1471-0528.13068

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

引用

页码：585 / 586

页数：2

共 50 条

[11] Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor
Agrawal, R
Chimusoro, K
Payne, N
van der Spuy, Z
Jacobs, HS
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1997, 9 (02) : 141 - 144
[12] Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: Effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase
BenArie, A
Weissman, A
Shoham, Z
HUMAN REPRODUCTION, 1996, 11 (06) : 1146 - 1148
[13] High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization
de Jong, D
Macklon, NS
Mannaerts, BMJL
Bennink, HJTC
Fauser, BCJM
HUMAN REPRODUCTION, 1998, 13 (03) : 573 - 575
[14] Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization
Fridén, BE
Nilsson, L
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2005, 84 (08) : 812 - 816
[15] Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome
Ludwig, M
Bauer, O
Lopens, A
Jelkmann, W
Diedrich, K
HUMAN REPRODUCTION, 1998, 13 (01) : 30 - 32
[16] Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
Abramov, Y
Barak, V
Nisman, B
Schenker, JG
FERTILITY AND STERILITY, 1997, 67 (02) : 261 - 265
[17] Gonadotrophin-releasing hormone analogue therapy does not decrease expression of vascular endothelial growth factor in uterine fibroids
Gentry, CC
Fong, LFWT
Perrett, CW
Okolo, SO
HUMAN REPRODUCTION, 2000, 15 : 171 - 172
[18] The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome
Rizk, B
Aboulghar, M
Smitz, J
RonEl, R
HUMAN REPRODUCTION UPDATE, 1997, 3 (03) : 255 - 266
[19] Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization
Beckers, NGM
Laven, JSE
Eijkemans, MJC
Fauser, BCJM
HUMAN REPRODUCTION, 2000, 15 (01) : 43 - 49
[20] Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases
Gurbuz, Ali Sami
Gode, Funda
Ozcimen, Necati
Isik, Ahmet Zeki
REPRODUCTIVE BIOMEDICINE ONLINE, 2014, 29 (05) : 541 - 544

← 1 2 3 4 5 →